In-Vivo Activated T-Cell Depletion to Prevent GVHD
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effects (good and bad) of the medication
basiliximab in combination with cyclosporine with cyclosporine alone for the prevention of
graft-versus-host disease.
This research is being done because there is no completely safe and effective prevention for
graft-versus-host disease. It is known that cyclosporine helps with GVHD but we would like to
know if the addition of basiliximab will decrease the incidence and/or severity of GVHD after
a transplant known as nonmyeloablative ("mini" transplant).